Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
暂无分享,去创建一个
Sidney C. Smith | K. Nasir | C. Ballantyne | N. Stone | S. Virani | Vijay Nambi | L. Petersen | E. Michos | P. Morris | Julia Akeroyd | V. Nambi